Literature DB >> 32313254

CRISPR off-target detection with DISCOVER-seq.

Beeke Wienert1,2, Stacia K Wyman3, Charles D Yeh4, Bruce R Conklin3,5,6, Jacob E Corn7.   

Abstract

DISCOVER-seq (discovery of in situ Cas off-targets and verification by sequencing) is a broadly applicable approach for unbiased CRISPR-Cas off-target identification in cells and tissues. It leverages the recruitment of DNA repair factors to double-strand breaks (DSBs) after genome editing with CRISPR nucleases. Here, we describe a detailed experimental protocol and analysis pipeline with which to perform DISCOVER-seq. The principle of this method is to track the precise recruitment of MRE11 to DSBs by chromatin immunoprecipitation followed by next-generation sequencing. A customized open-source bioinformatics pipeline, BLENDER (blunt end finder), then identifies off-target sequences genome wide. DISCOVER-seq is capable of finding and measuring off-targets in primary cells and in situ. The two main advantages of DISCOVER-seq are (i) low false-positive rates because DNA repair enzyme binding is required for genome edits to occur and (ii) its applicability to a wide variety of systems, including patient-derived cells and animal models. The whole protocol, including the analysis, can be completed within 2 weeks.

Entities:  

Mesh:

Year:  2020        PMID: 32313254      PMCID: PMC7305837          DOI: 10.1038/s41596-020-0309-5

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  28 in total

1.  Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.

Authors:  Bernd Zetsche; Jonathan S Gootenberg; Omar O Abudayyeh; Ian M Slaymaker; Kira S Makarova; Patrick Essletzbichler; Sara E Volz; Julia Joung; John van der Oost; Aviv Regev; Eugene V Koonin; Feng Zhang
Journal:  Cell       Date:  2015-09-25       Impact factor: 41.582

Review 2.  The MRE11 complex: starting from the ends.

Authors:  Travis H Stracker; John H J Petrini
Journal:  Nat Rev Mol Cell Biol       Date:  2011-02       Impact factor: 94.444

3.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

4.  UDiTaS™, a genome editing detection method for indels and genome rearrangements.

Authors:  Georgia Giannoukos; Dawn M Ciulla; Eugenio Marco; Hayat S Abdulkerim; Luis A Barrera; Anne Bothmer; Vidya Dhanapal; Sebastian W Gloskowski; Hariharan Jayaram; Morgan L Maeder; Maxwell N Skor; Tongyao Wang; Vic E Myer; Christopher J Wilson
Journal:  BMC Genomics       Date:  2018-03-21       Impact factor: 3.969

5.  CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.

Authors:  Shengdar Q Tsai; Nhu T Nguyen; Jose Malagon-Lopez; Ved V Topkar; Martin J Aryee; J Keith Joung
Journal:  Nat Methods       Date:  2017-05-01       Impact factor: 28.547

6.  Illuminating the genome-wide activity of genome editors for safe and effective therapeutics.

Authors:  Yong Cheng; Shengdar Q Tsai
Journal:  Genome Biol       Date:  2018-12-22       Impact factor: 13.583

7.  Role of mammalian Mre11 in classical and alternative nonhomologous end joining.

Authors:  Anyong Xie; Amy Kwok; Ralph Scully
Journal:  Nat Struct Mol Biol       Date:  2009-07-26       Impact factor: 15.369

8.  Defining CRISPR-Cas9 genome-wide nuclease activities with CIRCLE-seq.

Authors:  Cicera R Lazzarotto; Nhu T Nguyen; Xing Tang; Jose Malagon-Lopez; Jimmy A Guo; Martin J Aryee; J Keith Joung; Shengdar Q Tsai
Journal:  Nat Protoc       Date:  2018-11       Impact factor: 13.491

9.  An integrated encyclopedia of DNA elements in the human genome.

Authors: 
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

10.  A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells.

Authors:  Christopher A Vakulskas; Daniel P Dever; Garrett R Rettig; Rolf Turk; Ashley M Jacobi; Michael A Collingwood; Nicole M Bode; Matthew S McNeill; Shuqi Yan; Joab Camarena; Ciaran M Lee; So Hyun Park; Volker Wiebking; Rasmus O Bak; Natalia Gomez-Ospina; Mara Pavel-Dinu; Wenchao Sun; Gang Bao; Matthew H Porteus; Mark A Behlke
Journal:  Nat Med       Date:  2018-08-06       Impact factor: 53.440

View more
  11 in total

1.  CRISPR, animals, and FDA oversight: Building a path to success.

Authors:  Laura R Epstein; Stella S Lee; Mayumi F Miller; Heather A Lombardi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-30       Impact factor: 11.205

2.  LETR1 is a lymphatic endothelial-specific lncRNA governing cell proliferation and migration through KLF4 and SEMA3C.

Authors:  Luca Ducoli; Saumya Agrawal; Eliane Sibler; Tsukasa Kouno; Carlotta Tacconi; Chung-Chao Hon; Simone D Berger; Daniela Müllhaupt; Yuliang He; Jihye Kim; Marco D'Addio; Lothar C Dieterich; Piero Carninci; Michiel J L de Hoon; Jay W Shin; Michael Detmar
Journal:  Nat Commun       Date:  2021-02-10       Impact factor: 14.919

Review 3.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

Review 4.  Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.

Authors:  Wenyi Liu; Luoxi Li; Jianxin Jiang; Min Wu; Ping Lin
Journal:  Precis Clin Med       Date:  2021-07-10

Review 5.  Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.

Authors:  Paula Germino-Watnick; Malikiya Hinds; Anh Le; Rebecca Chu; Xiong Liu; Naoya Uchida
Journal:  Cells       Date:  2022-06-04       Impact factor: 7.666

6.  Cytosine and adenosine base editing in human pluripotent stem cells using transient reporters for editing enrichment.

Authors:  Stefan J Tekel; Nicholas Brookhouser; Kylie Standage-Beier; Xiao Wang; David A Brafman
Journal:  Nat Protoc       Date:  2021-06-25       Impact factor: 13.491

Review 7.  Development of CRISPR/Cas9 system for targeted DNA modifications and recent improvements in modification efficiency and specificity.

Authors:  Juhyun Shin; Jae-Wook Oh
Journal:  BMB Rep       Date:  2020-07       Impact factor: 4.778

Review 8.  Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.

Authors:  Muhammad Naeem; Saman Majeed; Mubasher Zahir Hoque; Irshad Ahmad
Journal:  Cells       Date:  2020-07-02       Impact factor: 6.600

Review 9.  Engineering chromosome rearrangements in cancer.

Authors:  Salvador Alonso; Lukas E Dow
Journal:  Dis Model Mech       Date:  2021-09-29       Impact factor: 5.732

10.  Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.

Authors:  Annalisa Lattanzi; Joab Camarena; Premanjali Lahiri; Helen Segal; Waracharee Srifa; Christopher A Vakulskas; Richard L Frock; Josefin Kenrick; Ciaran Lee; Narae Talbott; Jason Skowronski; M Kyle Cromer; Carsten T Charlesworth; Rasmus O Bak; Sruthi Mantri; Gang Bao; David DiGiusto; John Tisdale; J Fraser Wright; Neehar Bhatia; Maria Grazia Roncarolo; Daniel P Dever; Matthew H Porteus
Journal:  Sci Transl Med       Date:  2021-06-16       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.